Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2025-12-25 @ 7:36 PM
NCT ID:
NCT01920932
Group ID:
EG000
Title:
AEPA/CAPDac
Description:
Ann Arbor stage IIB, IIIB, IVA, or IVB participants receive:
2 cycles of AEPA chemotherapy:
(A) Brentuximab vedotin 1.2 mg/kg IV (intravenous) days 1, 8 and 15, (E) Etoposide 125 mg/m\^2 IV days 1-5, (P) Prednisone 60 mg/m\^2/day PO (orally) days 1-15, (A) Doxorubicin 40 mg/m\^2 IV days 1 and 15),
Followed by 4 cycles of CAPDac:
(C) Cyclophosphamide 500 mg/m\^2 IV days 1 and 8, (A) Brentuximab vedotin 1.2 mg/kg IV days 1 and 8, (P) Prednisone 40 mg/m\^2/day PO days 1-15, (Dac) Dacarbazine 250 mg/m\^2 IV days 1-3.).
Filgrastim 5 mcg/kg subcutaneous (SC) as clinically indicated.
For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy is given.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
77
Other Number Affected:
75
Other Number At Risk:
77
Study:
NCT01920932
Results Section:
NCT01920932
Adverse Events Module:
NCT01920932